133 related articles for article (PubMed ID: 22070369)
1. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
Bhattacharya SM; Ghosh M; Basu R
J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
Bhattacharya SM; Jha A
Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
[TBL] [Abstract][Full Text] [Related]
3. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
5. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
Sobbrio GA; Granata A; D'Arrigo F; Arena D; Panacea A; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):139-41. PubMed ID: 2149912
[TBL] [Abstract][Full Text] [Related]
7. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
8. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation.
Colonna L; Pacifico V; Lello S; Sorge R; Raskovic D; Primavera G
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1364-71. PubMed ID: 22011217
[TBL] [Abstract][Full Text] [Related]
9. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
[TBL] [Abstract][Full Text] [Related]
10. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2007 Mar; 12(1):30-5. PubMed ID: 17455042
[TBL] [Abstract][Full Text] [Related]
12. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
13. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.
Pasquali R; Gambineri A; Anconetani B; Vicennati V; Colitta D; Caramelli E; Casimirri F; Morselli-Labate AM
Clin Endocrinol (Oxf); 1999 Apr; 50(4):517-27. PubMed ID: 10468913
[TBL] [Abstract][Full Text] [Related]
14. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives.
Palatsi R; Hirvensalo E; Liukko P; Malmiharju T; Mattila L; Riihiluoma P; Ylöstalo P
Acta Derm Venereol; 1984; 64(6):517-23. PubMed ID: 6084924
[TBL] [Abstract][Full Text] [Related]
15. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
16. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.
Cagnacci A; Paoletti AM; Renzi A; Orrù M; Pilloni M; Melis GB; Volpe A
J Clin Endocrinol Metab; 2003 Aug; 88(8):3621-5. PubMed ID: 12915645
[TBL] [Abstract][Full Text] [Related]
17. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
Palatsi R; Reinilä M; Kivinén S
Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
[TBL] [Abstract][Full Text] [Related]
18. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
[TBL] [Abstract][Full Text] [Related]
19. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
[TBL] [Abstract][Full Text] [Related]
20. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
Harmanci A; Cinar N; Bayraktar M; Yildiz BO
Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
